Atea Pharmaceuticals (AVIR) Total Non-Current Liabilities (2019 - 2025)

Atea Pharmaceuticals' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $39.8 million for Q4 2025.

• On a quarterly basis, Total Non-Current Liabilities rose 104.6% year-over-year to $39.8 million in Q4 2025; TTM through Dec 2025 was $39.8 million, a 104.6% increase from a year earlier, with the FY2025 full-year figure at $39.8 million, up 104.6% from the prior year.
• Total Non-Current Liabilities climbed to $39.8 million in Q4 2025 per AVIR's latest filing, from $20.4 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $273.7 million in Q2 2021 and bottomed at $14.6 million in Q1 2023.
• The 5-year median for Total Non-Current Liabilities is $26.2 million (2024), against an average of $52.1 million.
• Across the five-year window, Total Non-Current Liabilities sank 89.81% in 2022 and jumped 193.33% in 2024, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $56.9 million in 2021, then plunged by 63.29% to $20.9 million in 2022, then soared by 62.91% to $34.0 million in 2023, then tumbled by 42.84% to $19.4 million in 2024, then jumped by 104.6% to $39.8 million in 2025.
• Per Business Quant, the three latest AVIR Total Non-Current Liabilities figures stand at $39.8 million (Q4 2025), $20.4 million (Q3 2025), and $20.5 million (Q2 2025).